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Abstract
Objective: Disease- and drug-related biomarkers are the basis of personalized medicine by guiding 
patient-specific clinical decisions. The methylene-tetrahydrofolate reductase (MTHFR) gene-associated C677T 
polymorphism has garnered particular attention because it can lead to an amino acid change resulting in a catalytically 
compromised enzyme. Here, we provide an alternative interpretation of C677T-associated MTHFR phenotypes that 
does not exclude the original hypothesis but rather places it in a different context. Our duon-based theory has 
practical implications as it facilitates the development of a new predictive biomarker for Rheumatoid Arthritis (RA) 
and Systemic Lupus Erythematosus (SLE). 
Methods: The new MTHFR promoter was identified using the 5’RACE method and functionally characterized 
in transient expression studies. Western blotting and confocal microscopy were used to investigate the subcellular 
localization of MTHFR isoforms. Expression of MTHFR transcript variants was monitored by qRT-PCR and a gene 
expression index (Li/Si score) was calculated from the Ct values.
Results: A new MTHFR isoform was identified, driven by a novel promoter region that overlaps with the site of 
the C677T polymorphism. Quantitative monitoring of the catalytically active and the catalytically inactive isoforms’ 
expression revealed that the proportion of MTHFR isoforms could be altered in PBMCs in a disease-specific manner. 
The calculated Li/Si scores were found to be characteristic for specific subgroups of RA and SLE patients.
Conclusion: Differential expression of MTHFR isoforms provides a foundation on which a predictive biomarker 
(Li/Si score) could be developed for RA and SLE reflecting disease susceptibility and drug response.
Keywords: MTHFR; C677T polymorphism; Duon; Rheumatoid 
Arthritis (RA); Systemic Lupus Erythematosus (SLE)
Introduction
Methylene-tetrahydrofolate reductase (MTHFR) plays 
a role in the folate cycle by catalyzing the conversion of 
5,10-methylenetetrahydrofolate into 5-methyltetrahydrofolate, which 
can be used in various metabolic events such as DNA and protein 
biosynthesis and epigenetic modifications [1]. The MTHFR gene gained 
more interest when high plasma homocysteine levels were found in 
patients with coronary heart disease [2] and the hyperhomocysteinemia 
was attributed to altered MTHFR activity caused by SNPs [3]. Since 
then, the field has rapidly expanded and over 4000 publications have 
focused on MTHFR polymorphism-implicated diseases including RA 
and SLE [4]. These publications were based on the assumption that 
diminished MTHFR activity results from the C677T polymorphism-
associated protein structure change but ignored the fact that reduced 
activity could only be detected after preincubating MTHFR proteins 
at non-physiological high temperatures [5]. However, recent genome-
wide studies reshaped the understanding of SNPs’ role in pathogeneses; 
it was found that the vast majority of the SNPs are located in non-
coding regions, therefore, their disease-promoting effects could be only 
explained by assuming that gene regulatory elements (i.e., Transcription 
factor (TF) binding sites) were affected [6,7]. In addition, the discovery 
of duons, TF binding sites in protein-coding regions, has practical 
implications for the interpretation of genetic variations [8,9]. Indeed, 
close to 15% of disease-associated SNPs identified by GWASs were 
located within duons and might be directly involved in pathological 
mechanisms by compromising both regulatory and/or structural 
functions of proteins. We hypothesized that the C677T polymorphism 
is within a duon, which would significantly affect the expression level 
of the MTHFR gene in addition to altering the amino acid sequence of 
MTHFR protein.
Molecular biomarkers are measurable indicators of normal and 
pathogenic processes and might also have the potential to predict 
favorable responses to therapy [10]. Rheumatology has traditionally 
relied on biomarkers and some of them have been incorporated into 
disease classification criteria  including erythrocyte sedimentation 
rate, C-reactive protein, rheumatoid factor, anticitrullinated protein 
antibodies, various anti-nuclear antibodies, anti-topoisomerase I (Scl-
70) antibody and anti-synthetase antibody [11]. Several novel molecular 
and clinical biomarkers have recently been identified, which can help 
in differential diagnosis, disease subset definition, or predicting the 
progression of organ damage [12]. Inflammatory rheumatic diseases 
are typically complex syndromes, therefore, patients in the same disease 
category can be genetically heterogeneous and therapeutic agents are 
usually effective on specific subsets of patients, which underpins the 
importance of biomarker-driven personalized therapy [13]. DMARD 
responsiveness-specific biomarkers have not been identified, and 
although whole-blood transcriptome analysis revealed promising 
expression panels for anti-TNF therapy responsiveness, no candidate 
biomarkers have progressed to becoming clinical diagnostic factors. 
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Accordingly, there is an obvious need for biomarkers that can predict 
the response to immunosuppressive treatments and to particular 
therapeutic agents. Methotrexate (MTX) is a first-line treatment 
option for newly diagnosed RA patients, but approximately 30% of RA 
patients develop MTX-related adverse drug events (ADEs), provoking 
discontinuation of MTX therapy [14]. In the context of MTX toxicity, 
the predictive biomarker potential of C677T polymorphisms has been 
investigated, but has resulted in contradictory conclusions [15].
Here, we report the discovery of a novel predictive biomarker (Li/
Si score) for RA and SLE, which can be informative regarding disease 
susceptibility and drug responsiveness, which can help guide clinical 
decisions.
Materials and Methods
Cell culture
The K562 cell line (ATTC CCL-243) was cultured in DMEM 
medium complemented with 10% fetal bovine serum. The cells cultures 
were maintained in a humidified incubator at 37°C with 5% CO2 in air. 
Study subjects
All patients and control individuals were recruited under an IRB-
approved protocol in Hungary. Signed informed consent was obtained 
from each subject. 
Controls: Healthy adults aged 19–65 years were recruited from 
the local community. Exclusion criteria were any chronic conditions 
including hypertension, allergy, diabetes, obesity and smoking. Control 
subjects had no infections and did not take NSAID one month before 
sampling. 
Patients: RA patients were diagnosed according to the latest ACR/
EULAR classification criteria [16] and MTX therapy and medium 
dose glucocorticoid therapy was initiated. Twenty-three of the 32 
RA patients received a variety of DMARDs, containing at least one 
of the following components: MTX, leflunomide, sulfasalazine or 
chloroquine. Eleven of the 32 RA patients received biologic therapy 
including anti-tumor necrosis factor (TNF) or IL6 receptor antagonist. 
SLE patients were diagnosed and classified according to the updated 
ACR97 criteria [17] at the time of sampling. All SLE patients had a 
moderate or a severe disease activity. SLEDAI scores were calculated 
at the time of sampling. Patients were treated with the following 
medications at onset of the SLE diagnosis and the two years after the 
diagnosis respectively: methylprednisolone (100%, 78.3%), chloroquine 
(100%, 78.3%), azathioprine (40.9%, 18.2%), cyclophosphamide 
(54.5%, 0%), methotrexate (27.3%, 13.7), cyclosporine (4,5%, 4.5%), 
and mycophenolate mofetil (13.6%, 9.1%), epratuzumab (0%, 4.5%), 
belimumab (0%, 4.5%), ustekinumab (0%,4.5%).
Total RNA isolation, cDNA synthesis and quantitative reverse 
transcription–polymerase chain reaction (qRT-PCR)
Peripheral blood mononuclear cells (PBMCs) were separated on 
a Ficoll gradient for RNA and DNA isolation. All of these procedures 
were conducted as previously described, but using CFX real-time PCR 
machine (Bio-Rad, Hercules, CA) for quantitative studies. Normal 
human tissue RNA samples were purchased as FirstChoice® Human 
Total RNA Survey Panel (Ambion, Austin, TX). Isoform-specific 
qRT-PCR primers were: Tr.v1F: ACATCTGTGTGGCAGGTTAC, 
Tr.v1R: GGAGTGGTAGCCCTGGAT and Tr.v2F: 
GTCATCCCTATTGGCAGGTTAC; Tr.v2R: 
GGAGTGGTAGCCCTGGAT. 
Determination of Li/Si score
Li/Si score calculation is similar to the fold differ-
ence calculation in qRT-PCR experiments. Accordingly
/  2Ct of Long MTHFR isoform Ct of Short MTHFR isoformLi Si score −=  values correspond to 
qRT-PCR measured threshold cycles. For example; if a Long MTHFR 
isoform’s Ct value is 27 and a Short MTHFR isoform’s Ct value is 29 
then Li/Si score is 27 292 0.25− = . This particular Li/Si score implies that 
the short MTHFR isoform’s expression level is ¼ of the long MTHFR 
isoform.
Genotyping of subjects
Nested PCR was employed to amplify C677T polymorphism 
carrying regions and PCR fragments were directly sequenced and 
the genotype was determined using Finch TV chromatogram viewer 
(Geospiza, Inc., Seattle, WA).
Rapid Amplification of cDNA Ends (5’RACE)
5’RACE was conducted on 1 µg of total RNA isolated from K562 
cells using FirstChoice RLM-RACE kit (Thermo-Fisher Scientific, 
Waltham, MA). Amplified 5’ MTHFR transcript ends were cloned, 
sequenced, and data were deposited into NCBI GenBank (JQ429447).
Western blotting
Sub-cellular protein fractions were prepared using Nuclei EZ Prep 
nuclei isolation kit (Sigma-Aldrich, Saint Louis, MO). Western blotting 
was performed as described before. C-terminal specific anti-MTHFR 
antibody (GTX88281, Lot. No. 821604005) was purchased from 
GeneTex (Irvine, CA).
Immunofluorescence microscopy
K562 cells were fixed and incubated with IM7.8.1-Alexa Fluor 488 
conjugated antibody to detect membrane-bound CD44+. After the 
cells were blocked and stained with C-terminal specific anti-MTHFR 
antibody (GTX88281). Rabbit anti-goat IgG-Texas Red (H+L) (Vector 
Laboratories, Burlingame, CA) was used as a secondary antibody to 
detect intracellular MTHFR. Nuclear counterstaining was performed 
with DAPI. A Zeiss LSM 700 confocal microscope and ZEN 2.3 imaging 
software were used to detect and analyze subcellular localization of 
MTHFR isoforms.
Luciferase reporter gene assays
The two different C677T alleles carrying intronic promoters were 
cloned into pGL4.19 Luciferase reporter vector (Promega, Madison, 
WI). Recombinant constructs were electroporated into 5x106 K562 
cells and cells were lysed in 400 μL of 1X Cell Culture Lysis Reagent 
(Promega, Medison, WI) after 24 hours. Luciferase activity was 
measured by using 20 µL of lysate and 100 µL of Luciferase Assay 
Reagent (Promega, Medison, WI) in Single Tube Luminometer 
(Titertek-Berthold, Pforzheim, Germany).
Statistical analysis
Fisher’s exact test was used for calculation of statistical significance 
of small sample sizes [18].
Results
MTHFR could be considered as a gatekeeper enzyme for epigenetic 
processes [1]; therefore, we investigated how epigenetic signals could 
affect its own expression. Epigenetic histone signals, downloaded 
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from the ENCODE database [19], that are known for defining 
transcriptionally active promoter regions [20] forecasted the presence of 
a new supplementary promoter for MTHFR. Interestingly, the predicted 
promoter harbors the C677T polymorphism (Figure 1A), which 
implies that it might affect its activity. By employing 5’RACE method 
[21] we identified a new MTHFR transcript variant (Trc.v2), which was 
initiated from the forecasted promoter region (i.e., in MTHFR intron 
3) (Figure 1B). Thus, the first three exons were missing from the Trc.
v2 transcript and it could encode only a truncated MTHFR isoform 
carrying the regulatory domain of the enzyme [22]. Localization of 
the short MTHFR isoform was investigated in subcellular fractions by 
Western blotting using a C-terminus specific antibody. The full length 
MTHFR isoform dominated in the cytoplasmic fraction but the short 
MTHFR isoform could be detected in nuclear lysates (Figure 1C). 
Nuclear localization of the short MTHFR isoform was confirmed by 
confocal microscopy (Figure 1D). The tissue-specific expression of the 
new MTHFR isoform was explored in 20 normal human tissue samples 
using isoform-specific qRT-PCR. The short MTHFR transcript variant 
(Trc.v2) was ubiquitously expressed together with the full-length 
MTHFR coding variant (Trc.v1). The absolute expression levels of the 
two isoforms varied among tissues. Therefore, to compare MTHFR 
isoform expression between tissues (and later between patients), we 
introduced the Li/Si score that reflects the fold expression difference 
between the long (Li) and the short (Si) transcript variants. According 
to these data, the newly described MTHFR isoform is expressed at 
low levels in all normal tissues together with the full length MTHFR 
isoform (Figure 2A).
Next, we compared the transcript variants’ (Trc.v1 and Trc.v2) 
expression in PBMCs isolated from 32 newly diagnosed (treatment 
naive) patients with active RA, 23 newly diagnosed (treatment naive) 
patients with active SLE, and 22 healthy age-matched controls. Li/Si 
scores were calculated from qRT-PCR values and compared to clinical 
phenotypes. By using Li/Si scores, control individuals, RA and SLE 
patients could be divided into 3 classes. Class-defining threshold values 
were determined on the basis of the observed Li/Si scores in 20 normal 
tissue samples (Figure 2A) and the 22 control PBMC samples (Figure 2B). 
Accordingly, Class A individuals had Li/Si scores <0.65, Class B included 
individuals with Li/Si scores between 0.65 – 2.0 and Class C individuals 
had Li/Si scores >2.0. We found that low Li/Si scores (Class A) were 
characteristic for control individuals (82%, p<0.01) (Figure 3A). The 
intermediate Li/Si score (Class B) was exclusively characteristic of RA 
(46.8%, p<0.01, OR: 8.438, 95% CI: 2.118 - 8.813) and SLE (65.2%, 
p<0.01, OR: 9.643, 95% CI: 2.362 – 11.049) patients (Figure 3B). In 
addition, we found that RA and SLE patients with intermediate Li/
Si scores (Class B) were prone to ADEs, including hepatotoxicity and 
gastrointestinal complaints for RA, and gastrointestinal complaints, 
fever, and hepatitis for SLE patients. 
RA patients with intermediate Li/Si scores had a 19% chance 
(p<0.01, OR: 27, 95% CI: 2.503 - 20.328) of developing ADE, while 
SLE patients had 39% chance (p<0.01, OR: 36, 95% CI: 3.453 - 37.524) 
(Figures 3B and 3C). Interestingly, the subjects with high Li/Si values 
(Class C) were relatively frequent among controls (13.6%, p=0,0986, 
OR: 0.25, 95% CI: 0.058, 0.00795) and RA patients (28.1%, p<0.05, OR: 
5.062, 95% CI: 1.196 – 2.966) but scarce among SLE patients (4.3%, 
p=1, OR: 0.643, 95% CI: 0.061 – 0.014) (Figure 3).
Next, we genotyped all subjects by sequencing the C677T 
polymorphism-carrying region and investigated how allele frequencies 
and Li/Si scores correlated with diseases. We found that T allele-carrying 
individuals were over-represented among control subjects (77.27%) 
compared to RA (40%, p<0.05) or SLE (34.7%, p<0.01) patients, but 
further correlation could not be found between C667T alleles and 
diseases. These findings indicated that the C677T polymorphism itself 
has a limited potential as a biomarker, but the Li/Si scores could indicate 
susceptibility to diseases (i.e., RA and SLE) and ADE (Figure 3). We 
also investigated whether a single C to T nucleotide switch that simulate 
C667T polymorphism had effect on reporter gene (i.e., Luciferase) 
activity in transient expression studies. The C-allele carrying promoter 
 
Figure 1: MTHFR gene transcripts and encoded protein isoforms. A: Schematic diagram of the MTHFR gene. Top: genomic structure of the gene is shown. The 
numbered black boxes refer to the exons. Below the gene: transcript variants (Trc.v1 and Trc.v2) of MTHFR identified in K562 cells. Open boxes indicate the 5’ and 3’ 
untranslated regions. Intronic sequences are shown as thin lines. B: Enlarged view of 3’ end of intron 3 and exon 4. Asterisk indicates the location of C677T (rs1801133). 
C: Detection of MTHFR isoforms by Western blotting. Fractionated K562 cell extracts were probed with C-terminus-specific anti-MTHFR antibody. WCE – whole cell 
extract, CpF - cytoplasmic fraction, Nucl.E – eluted nuclear fraction [nuclear envelope was preserved during elution], Nucl.L. - nuclear lysates [nuclear envelope was 
destroyed during elution]. Red arrows point to cytoplasm-specific MTHFR isoforms. Black arrows indicate nucleus-specific MTHFR isoforms. D: Subcellular localization 
of MTHFR isoforms. Detection of MTHFR isoforms in K562 cells by confocal microscopy. Blue: DAPI stained nucleus, Red: MTHFR-specific staining with C terminus-
specific anti-MTHFR. Green: Cell membrane-specific staining with anti-human CD44 antibody, Bar: 10 µm.
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Figure 2: Expression of MTHFR isoforms in human tissue and PBMC samples. Isoform-specific PCR Ct values were used to calculate the Li/Si scores. The Li/Si score 
represents the relative expression difference (fold-difference) between the long MTHFR (Li) and short MTHFR isoform (Si). The expression level of the long isoform 
is considered 1 in each case. Li/Si scores in A: normal human tissue samples, B: PBSCs of control human subjects, C: PBSCs of RA patients and D: PBSCs of SLE 
patients. Dotted lines mark the class-defining 0.65 and 2.0 Li/Si scores described in the Results.
provoked 20% (p<0.05) higher Luciferase activity than the T-harboring 
allele indicating allele-dependent promoter activity.
Discussion
Epigenetic histone signal profiles predicted the existence of an 
intragenic MTHFR promoter, which proved to be active in subsequent 
studies (Figure 1). The novel MTHFR promoter was located in intron 
3, and the corresponding transcript encoded a truncated MTHFR 
isoform with unknown function in the nucleus. What makes the 
intronic MTHFR promoter even more interesting is that the C677T 
polymorphism resides in exon 4 and overlaps with this promoter 
(Figure 1B). Transient expression studies revealed that the T-allele was 
associated with low expression of the novel transcript variant (Trc.v2), 
which is characteristic for the control (healthy) individuals. Accordingly, 
 
Figure 3: Li/Si scores and SNP genotypes in human PBMC samples. Pie-of-pie charts demonstrate Li/Si score and ADE distribution in human subjects. SNP distributions 
are summarized under the corresponding pie-of-pie charts. SNP: actual genotype of C677T polymorphism. n: number of the investigated subjects. Asterisks label 
patients with ADEs.
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the low Trc.v2 expression is protective against the investigated diseases 
and C677T is part of a bona fide duon since it encodes an internal part 
of the full-length MTHFR, and as part of the intronic promoter, it 
affects the expression of the truncated MTHFR isoform.
By exploring Li/Si scores in 22 control individuals and 55 patients 
(32 RA and 23 SLE) we took the first steps toward evaluating Li/Si score 
as a potential biomarker. On the basis of the observed Li/Si scores, we 
defined 3 levels (low, intermediate and high Li/Si score classes), which 
can be linked to disease susceptibility. Notably, the current threshold 
values could be further specified after extended studies for larger 
patient populations. Although healthy individuals dominantly possess 
low Li/Si scores (Class A), similar Li/Si values could also be detected 
in RA (25%, p<0.01, OR: 0.074, CI: 0.019, 0.0009) and SLE (30.4%, 
p<0.01, OR: 0.097, CI: 0.024, 0.001) patients (Figure 3), which can be 
attributed to the polygenic nature of diseases implicated more decisive 
risk regions. RA and SLE. Intermediate Li/Si scores (Class B) were 
found to be exclusive for RA and SLE patients, and a subpopulation 
of these subjects were also prone to ADEs. Specifically, patients with 
intermediate Li/Si scores tend to develop hypersensitivity to DMARDs, 
including MTX, azathioprine, chloroquine and naltrexone. The link 
between Li/Si score and MTX toxicity can be explained by the fact that 
this drug inhibits the folate cycle in which MTHFR plays a role, and the 
disease-associated imbalance of MTHFR isoform expression might also 
trigger ADEs. However, the other DMARDs, including azathioprine, 
chloroquine and naltrexone, are involved in different pathways, and it 
is unclear how Li/Si scores relate to the adverse reactions to these drugs.
Conclusion
Application of the Li/Si score might help guide clinical decisions 
regarding therapeutic intervention in several ways by identifying patients 
with a high tolerance toward DMARDs (Class A and Class C) who might 
benefit from an increased dose. On the other hand, individuals with 
potential ADEs (Class B) could be treated more carefully to minimize 
DMARD induced toxicity. Since ADE prone individuals constitute a 
subpopulation among patients with intermediate Li/Si scores (Class B), 
it will be essential to identify additional factors that could be used to 
discriminate between the DMARD sensitive and insensitive subjects. 
The Li/Si score in its current form has shown potential as a predictive 
biomarker in RA and SLE patient populations. To be widely used as 
a biomarker, the Li/Si score must be assessed in an extended patient 
cohort, and further studies should be conducted to validate the 
threshold values of Li/Si score-based classifications. The discovery and 
preliminary validation of Li/Si score in this study might have an impact 
on the use of DMARDs in rheumatic disorders and that the Li/Si score 
has the potential to become the first non-serological predictive test in 
RA and SLE.
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